New Taxotere(R) (docetaxel) Injection Concentrate Data to be Presented at the 30th Annual San Antonio Breast Cancer Symposi...(/m2 Epirubicin 100 mg/m2 Cyclophosphamid...),Health

-- Taxotere(R) data in the neoadjuvant setting will also be presented:

Abst 79: "Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide >> docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study "GeparQuattro" >>. von Minckwitz G, et al.

Sunday, December 16, 2007, 11:00 AM / General session 7, Exhibit Hall D

Prior to surgery, patients were treated with epirubicin and

cyclophosphamide followed by either Taxotere(R) alone

(100 mg/m squared), Taxotere(R) (75 mg/m squared) combined with

capecitabine (1800 mg/m squared), or Taxotere(R) (100mg/m2) followed

by capecitabine (1800mg/m2). The primary endpoint of the study is the

pathologic complete response at surgery.

-- Data from another investigational non-anthracycline Taxotere(R)-based

regimen will be presented from a study in patients with advanced HER2

positive breast cancer:

Abst 309: "Evaluation of trastuzumab, docetaxel and capecitabine as first- line therapy for HER2-positive locally advanced or metastatic breast cancer." Wardley A, et al.

Friday, December 14th, 2007 5:00-7:00 PM / Poster discussion session 3, Antibodies and Immunotherapy - Ballroom B

About Breast Cancer

Breast cancer is the most frequently diagnosed cancer in women. It is the second-leading cause of cancer death in women after lung cancer, and since 1990 is increasing predominantly in women 50 and over. It is the first cause of cancer mortality in women of 40 to 59 years old. According to the American Cancer Society, an estimated 200,000 women are diagnosed with breast cancer and approximately 40,000 women die of the disease in the United States every year. A woman is diagnosed with breast cancer in the United States every three m
'/>"/>